The European Parliament’s public health committee adopted its proposals to enhance the availability of key medicines in the EU, aimed to ensure a high level of public health protection for EU citizens by reducing the EU’s dependency on third countries and boosting the competitiveness of its pharmaceutical sector.

The report requires the EU, including through regional funding, and EU member states to prioritise financial support for strategic projects, as well as a dedicated “critical medicines security fund” to be established within the EU’s next multiannual financial framework.

Parliament’s position is expected to be adopted during the January 2026 plenary session, after which negotiations with EU governments can begin.